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ABSTRACT
Major breast cancer predisposition genes, only account for approximately 30% of 
high-risk breast cancer families and only explain 15% of breast cancer familial relative 
risk. The HGF growth factor receptor MET is potentially functionally altered due to an 
uncommon germline single nucleotide polymorphism (SNP), MET-T1010I, in many 
cancer lineages including breast cancer where the MET-T1010I SNP is present in 2% 
of patients with metastatic breast cancer. Expression of MET-T1010I in the context 
of mammary epithelium increases colony formation, cell migration and invasion in-
vitro and tumor growth and invasion in-vivo. A selective effect of MET-T1010I as 
compared to wild type MET on cell invasion both in-vitro and in-vivo suggests that 
the MET-T1010I SNP may alter tumor pathophysiology and should be considered as 
a potential biomarker when implementing MET targeted clinical trials. 
INTRODUCTION
A strong breast cancer family history can signal 
the presence of inherited risk-modifying genetic events. 
However, mutations in BRCA1/2, the major breast cancer 
predisposition genes, only account for approximately 
30% of high-risk breast cancer families and only explain 
15% of breast cancer familial relative risk [1-5]. Even 
including the estimated contributions of mutations in high 
penetrance (BRCA1/2, TP53, CDH1, LKB1, and PTEN), 
and moderate or low penetrance genes including SNPs 
associated with breast cancer identified through genome-
wide association studies (GWAS), 50% of familial breast 
cancer predisposition still remains unexplained [6].
The hepatocyte growth factor (HGF) and its 
receptor, the transmembrane tyrosine kinase MET, 
promote cell proliferation, survival, motility, and invasion, 
as well as morphogenic changes that can stimulate repair 
and regeneration in normal tissues. The greatest effects 
of HGF, also known as scatter factor, are most clearly 
manifest through cellular motility and invasion. As with 
many growth factor receptors, the actions of MET are 
co-opted during tumor growth [7]. MET over-expression, 
with or without gene amplification has been reported in a 
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variety of human malignancies [7-10] where it has been 
suggested to provide a major resistance mechanism for 
targeted therapies against multiple receptors [7]. Non-
synonymous germ-line mutations in the kinase domain of 
MET were initially described in patients with hereditary 
papillary renal carcinoma [11]. Sporadic and germline 
MET mutations have since been detected in multiple solid 
tumors. However, only a subset of these mutant alleles 
have been proven to cause malignant transformation 
providing a potential for therapeutic targeting [12]. 
In many cases, the impact of germline and somatic 
aberrations remains controversial and is likely context 
dependent with different effects based on intrinsic lineage 
expression programs or mutational context in particular 
cancer lineages. 
Here we report that the MET-T1010I germline 
mutation occurs in approximately 2% of patients with 
metastatic breast cancer. Overexpression of wild type 
MET (MET-WT) as well as expression of MET-T1010I 
increases colony formation, cell migration and invasion 
in-vitro and tumor growth in-vivo. A selective effect of 
MET-T1010I on cell invasion both in-vitro and in-vivo 
as compared to MET-WT suggests that MET-T1010I 
may alter pathophysiology and should be considered for 
inclusion in clinical trials of MET inhibitors.
RESULTS
Matched tumor tissue and blood from 240 patients 
with metastatic breast cancer were submitted for targeted 
exome sequencing. Three somatic mutations (MET-
M1192I, MET-L269V, and MET-E34K) were found 
in three different patients. We also found 19 germline 
mutations in 18 patients (one patient had two germline 
mutations). Figure 1A shows the MET germline mutations 
detected in patients with metastatic breast cancer, and 
their frequencies as compared with a normal population 
with a similar ethnic mix (1000 Genomes Project, 
www.1000genomes.org). Two recurrent germline 
mutations (as these SNPs are potentially functional) MET-
N375S (n = 9) and MET-T1010I (n = 5) were observed. 
The frequency of MET-T1010I in patients with metastatic 
breast cancer was twice that in the general population 
(Odds Ratio [OR] = 2.09, 95% CI: 0.72−6.07). Based on 
the odds ratio of 2.0, we decided to assess the functional 
consequence of MET-T1010I in breast cancer models. 
Table 1 shows the patient characteristics assessed by MET 
Figure 1: Germline mutations and survival estimates in metastatic breast cancer. Tumor and blood samples were obtained 
under an Institutional Review Board-approved prospective collection protocol at MD Anderson Cancer Center (MDACC). After informed 
consent, patients with metastatic breast cancer underwent biopsy of their metastatic disease and blood collection. For genomic DNA 
library preparation, and target capture, whole exome sequencing and data analysis, we called single nucleotide variants (SNVs) and small 
indels using an in-house developed analysis pipeline based on variant allele frequencies in the tumor and the matched normal tissues. (A) 
Germline MET mutations detected in patients with metastatic breast cancer, and their frequencies as compared with normal population 
(1000 Genome Project). (B) Overall survival outcomes of patients with MET germline mutations versus patients with wild type MET.
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germline mutation status. At a median follow-up of 44 
months (range, 5−384 months), there were 69 (28.7%) 
deaths. Five-year OS was 82% in MET mutation carriers 
and 71% in patients without MET mutations, (P = 0.18), 
respectively (Figure 1B). These are not significantly 
different from the outcomes for patients without germline 
aberrations but are limited by the low number of events in 
the MET mutation population.
To determine if MET-T1010I alters breast cancer 
pathophysiology, we compared its effects to MET-
WT representing MET overexpression in breast cancer 
and to MET-Y1253D tyrosine kinase domain mutation 
representing an activated MET receptor. First, to evaluate 
the effects of MET aberrations on cell signaling, we tested 
the expression and phosphorylation levels of endogenous 
and exogenous MET and its downstream targets, including 
phosphorylation of AKT, MAPK and STAT3 with Western 
blotting (Figure 2A). MET-WT and MET-T1010I were 
markedly overexpressed with MET-T1010I expressed to 
slightly higher levels than MET-WT potentially due to 
decreased turnover due to interference with the effects 
of Y1003-mediated phosphorylation and degradation 
[13]. In contrast MET-Y1253D was expressed to modest 
levels potentially due to increased internalization and 
degradation of activated MET receptors [13]. Under basal 
conditions, all three constructs demonstrated increased 
MET phosophorylation (pY1234/1235) consistent with 
constitutive activation. Under basal conditions, MET 
transfected cells, regardless of the construct, demonstrated 
a modest but consistent increase in phophorylation of 
MAPK consistent with activation of the MET receptor. 
There was a slight increase in phosphorylation of AKT 
and STAT3 with the MET-T1010I construct compared to 
the other constructs. 
To investigate whether MET-T1010I affects cell 
survival, we performed clonogenic assays. In the presence 
of HGF, MET-WT and the two mutants (T1010I, Y1253D) 
markedly increased colony formation and colony size 
compared to control cells in low serum medium in the 
absence of EGF and insulin which are required for optimal 
proliferation of MCF-10A (Figure 2B). Interestingly, both 
MET mutants, but not MET-WT or control, induced colony 
formation in the absence of HGF, with MET-T1010I 
inducing more and larger colonies than MET-Y1253D 
(Figure 2C), suggesting that MET mutants are less 
dependent on HGF than WT MET. In a three-dimensional 
Matrigel culture system in the presence of HGF, MCF-
10A cells expressing MET-T1010I formed larger acini 
with abnormal structures, scattering to the surrounding 
matrix (Figure 2D). WT MET cells showed similar 
but milder morphological alterations. In contrast, cells 
expressing MET-Y1253D did not demonstrate detectable 
invasion into Matrigel. In contrast, MET-Y1253D cells 
had normal structure but formed larger acini than control 
Table 1: Patient and tumor characteristics
All Patients
(N = 240)
MET Germline 
Wildtype
 (N = 222)
MET Germline 
Mutation
(N = 18)
N (%) N % N % P
Age, years
        Age ≤ 50 163(67.9%) 151 68.0 12 66.7
        Age > 50 77(32.1%) 71 32.0 6 33.3 0.90
Nuclear grade
I 6(2.6%) 5 2.4 1 5.6
II 63(27.4%) 59 27.8 4 22.2
III 161(70%) 148 69.8 13 72.2 0.42*
Subtype
Hormonal positive 114(59.1%) 104 58.4 10 66.7
HER2 positive 25(13%) 25 14.0 0 0.0
Triple negative 54(28%) 49 27.5 5 33.3 0.36*
Lymphovascular Invasion
       Negative 114(52.3%) 99 49.5 15 83.3
       Positive 104(47.7%) 101 50.5 3 16.7 0.006*
Neoadjuvant therapy
No 165(68.8%) 150 67.6 15 83.3
Yes 75(31.3%) 72 32.4 3 16.7 0.19*
Adjuvant Therapy
No 71(29.6%) 67 30.2 4 22.2
Yes 169(70.4%) 155 69.8 14 77.8 0.59*
*Fisher’s exact p-value.
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Figure 2: Transforming effects of MET aberrations in breast epithelial cells. (A) Effects of MET aberrations on cell signaling: 
Lysates of MCF-10A derived cells (as indicated) were used for Western blot. Effects of MET aberrations on colony formation were tested 
as described in Materials and Methods. MCF-10A derived cells (as indicated) were seeded in triplicate. Cells were cultured in 2.5% 
horse serum, lacking EGF and insulin, with HGF (40 ng/ml) (B) or without HGF (C). Photos were taken at day 11. Data are mean ± 
standard error of triplicates, representative of two independent experiments (*, P < 0.0001 versus Vector). ANOVA. (D) Effects of MET 
aberrations on mammary acinar morphogenesis were tested as described in Materials and Methods. MCF-10A derived cells (as indicated) 
were resuspended in modified growth medium containing 2% matrigel, 2% horse serum, and 5 ng/mL EGF, supplemented with HGF 40 
ng/ml. Representative field images of acini were taken on day 8; original magnification, X40. Effects of MET overexpression or mutations 
on cell invasion were tested as described in Materials and Methods. MCF-10A derived cells (as indicated) were induced with fibronectin (5 
μg/ml)   alone (E) or both HGF (40 ng/ml) and fibronectin (5 μg/ml) (F). Cells were photographed at X100 magnification. Data are mean ± 
standard errors of triplicates, representative of two independent experiments. (*, P < 0.0001 versus Vector). ANOVA. 
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cells, suggesting that mutant MET (MET-T1010I) and 
overexpression of WT MET in the presence of HGF 
promote both cell proliferation and invasion in Matrigel, 
whereas MET-Y1253D increased cell proliferation but not 
invasion. However, in a Boyden chamber invasion assay, 
even in the absence of HGF, both MET mutations (T1010I 
and Y1253D) were sufficient to significantly increase 
invasion (P < 0.0001), with the T1010I mutant exhibiting 
greater invasive capacity than Y1253D (P < 0.0001) 
(Figure 2E). Further, MET-WT increased invasiveness in 
the presence of HGF (Figure 2F). 
To determine whether MET overexpression or 
mutation was sufficient to induce tumor formation and 
invasion in-vivo, we established tumor xenograft models 
in human HGF transgenic mice on a severe combined 
immunodeficiency (SCID) background, named hHGF Tg 
SCID [14]. As expected, vector-transfected MCF-10A 
cells did not form tumors. Furthermore, only one hHGF 
negative mouse of 5 injected with MET-T1010I expressing 
tumor cells developed a tumor and none of the MET-WT 
or MET-Y1253D cohorts developed tumors indicating that 
human HGF is required for optimal tumor development 
in SCID mice. Tumors grew in all mice in the MET-WT 
group (9/9) and most mice in the MET-T1010I (7/9) cohort 
with 8- and 12-day latent periods respectively, while only 
3/7 mice in the MET-Y1253D cohort formed tumors which 
were both much smaller and had a longer latent period (20 
days) (Figure 3A). Tumor weight in MET-WT group was 
higher than that in MET-T1010 and MET-Y1253D groups 
(P < 0.0001, respectively) (Figure 3B). 
Xenograft tumors and all organs of each mouse 
were processed into hematoxylin and eosin (H&E) 
stained sections, which were examined and evaluated 
histopathologically by a veterinary pathologist blinded 
to the genotype of the tumors. Tumors were evaluated 
histologically (cellular density and morphology, 
mitotic rate, and invasion into surrounding tissues), 
and all other organs were examined for the presence of 
tumor metastasis. All tumors from the MET-WT and 
MET-T1010I groups showed dense cellularity with 
Figure 3: Effects of MET aberrations on MCF-10A xenograft in hHGF transgenic mice. (A) A total of 1x107 MCF-10A 
derived cells (as indicated) were injected into the mammary fat pad of hHGF/SCID females. Each group consisted of 7-9 mice. Tumor 
volume was calculated with the formula (V = lw2/2) (Mean ± SEM; ANOVA, *, P < 0.05 MET-WT versus T1010I, Y1253D and Vector 
groups, respectively). (B) Tumor weight. (*, P < 0.05 compared with T1010I, Y1253D and Vector groups, respectively). ANOVA. (C) 
H&E for histological images from representative tumor from MET-WT, MET-T1010I and MET-Y1253D. All tumors from the MET-WT 
and MET-T1010I groups showed dense cellularity with undifferentiated and markedly pleomorphic tumor cells (ptc), and high mitotic 
rate. In contrast, tumors from MET-Y1253D had significantly lower cellularity with less pleomorphic and well-differentiated tumor cells 
forming glandular and acinar structures (green arrows). Compared to tumors from the MET-WT group, MET-T1010I tumors exhibited 
more aggressive invasion (black arrows) into surrounding adipose tissue and skeletal muscle (sm). (D) Data are presented as grade of tumor 
invasion (*, P < 0.05; **, P < 0.01; ***, P < 0.0001 versus Vector). ANOVA. 
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undifferentiated and markedly pleomorphic tumor cells 
(ptc), and high mitotic rate. In contrast, tumors from 
MET-Y1253D had significantly lower cellularity with 
less pleomorphic and more well-differentiated tumor 
cells forming glandular or acinar structures (green 
arrows). Compared to tumors from the MET-WT group, 
MET-T1010I tumors exhibited more aggressive tumor 
invasion (black arrows) into surrounding skeletal muscle 
(sm) (Figure 3C). Local or peripheral infiltration of 
tumor cells into surrounding adipose, skeletal muscle or 
mammary gland tissues were graded into 5 levels (0−4) 
by a veterinary pathologist (Figure 3D). Consistent with 
the in-vitro data, MET-T1010I tumors exhibited aggressive 
invasion into surrounding tissues. No metastasis was 
detected at the 28-day time-point in any group.
DISCUSSION
We demonstrate that MET germline mutations occur 
in 7% of patients with metastatic breast cancer with MET-
T1010I found in 2% of patients. This was not detected in 
the Collaborative Oncological Gene-environment Study 
(COGS) potentially due to our study being restricted to 
patients with metastatic breast cancer [4,6]. More recently, 
Kurian et al. performed targeted exon sequencing of 
42 genes including MET in the germline DNA of 198 
women referred for BRCA testing, 174 with breast cancer. 
This study of limited size also failed to detect germline 
mutations in MET [15]. In contrast, the MET-T1010I SNP 
has been reported to be associated with hereditary renal 
papillary cancer, non-small cell lung cancer, colon cancer, 
and gastric cancer and has been found in a patient with 
breast cancer [12,16-18]. In our study, germline MET-
T1010I mutations are in excess of the numbers predicted 
based on allele frequency in the 1000 Genomes Project in 
metastatic breast cancer, however, due to the low number 
of cases, this did not reach significance.
We did not detect survival differences between MET 
mutation carriers and non-carriers in this small sample 
set. In survival studies looking at the prognostic effect 
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of BRCA1/2 mutation in breast cancer, no OS differences 
have been demonstrated. However, BRCA mutations have 
been associated with longer recurrence-free survival in 
triple-negative disease [19]. However, larger studies will 
be required to determine whether these SNPs in MET are 
associated with altered patient outcomes.
Somatic and germline mutations in MET are 
predominantly located in the non-kinase domain, 
mainly in regions encoding the extracellular semaphorin 
domain (E168D, L229F, S323G, and N375S) and the 
intracellular juxtamembrane domain (R988C, T1010I, 
S1058P, and exon-14 deletions) [20]. However, only 
some of these mutant alleles have been proven to cause 
malignant transformation as a result of constitutive 
receptor activation posing a potential for therapeutic 
targeting or altering response to therapy targeting other 
signaling molecules [12]. The MET juxtamembrane 
domain regulates ligand-dependent MET internalization 
as a consequence of Y1003 phosphorylation in response 
to HGF binding leading to MET ubiquitination and 
degradation [13]. Mutations in the juxtamembrane 
domain such as T1010I have been proposed to result 
in MET accumulation at the cell surface and persistent 
signaling leading to tumorigenic activity [13]. Indeed in 
our studies when expressed in MCF-10A as compared 
to a constitutively active MET variant, MET-T1010I is 
expressed at an elevated level potentially contributing to 
its selective effect on invasion in-vitro and in-vivo. Though 
some previous reports suggested that MET-T1010I could 
have oncogenic properties, the results of functional studies 
are contradictory. Schmidt et al. proposed that the T1010I 
mutation is a SNP as it lacked the ability to transform 
NIH-3T3 cells [11]. Tyner et al. found similar results in the 
BA/F3 murine myeloid cell model [21]. In contrast, Lee 
et al. found tumorigenic effects in their NIH-3T3 model 
[17], and Tengs et al. reported the transforming potential 
of MET-T1010I in non-small cell lung cancer [22]. We 
demonstrate that MET-T1010I has marked functional 
consequences in the MCF-10A normal breast epithelial 
cell line, which is more likely to reflect the appropriate 
context for breast cancer than previous studies with BA/F3 
and NIH-3T3. Interestingly, our data showed differences 
between effects of the somatic activating MET mutation, 
MET-Y1253D, and the germline MET-T1010I. Despite a 
low level of expression in MCF-10A compared to MET-
WT, MET-Y1253D increased cell survival independent of 
exogenous HGF in vitro, suggesting that increased kinase 
activity is sufficient for these processes. However, in 
contradistinction to MET-WT and MET-Y1253D, MET-
T1010I selectively increases invasion both in-vitro and in-
vivo. This effect of MET-T1010I is not fully recapitulated 
by an activating mutation in the tyrosine kinase domain or 
by overexpression of MET-WT suggesting that the effects 
of MET-T1010I are not solely due to overexpression or 
due to increased kinase activity. Whether this selective 
effect relates to increased MET-T1010I stability [13] will 
require further exploration. 
Exogenous expression of MET-T1010I resulted 
in a modest increase in expression of exogenous MET-
Flag and endogenous MET compared to the other 
constructs. This was associated with a slight increase in 
basal phosphorylation of MET, MAPK, AKT and STAT3. 
However, these differences compared to MET-WT or 
MET-Y1253D were modest. As indicated above, decreased 
levels of MET-Y1253D in MCF-10A cells are consistent 
with phosphorylation-mediated degradation [23]. Since the 
juxtamembrane domain regulates ligand-dependent MET 
internalization as a consequence Y1003 phosphorylation 
leading to MET ubiquitination and degradation [13], the 
MET-T1010I SNP in the juxtamembrane domains may 
contribute to MET accumulation at the cell surface and 
persistent pathway activation contributing to effects on 
tumor pathophysiology [13].
In conclusion, we found MET germline mutations 
in 7% of patients with metastatic breast cancer, with at 
least one of the SNPs contributing to aggressive behavior 
when expressed in the MCF-10A cell model. Our 
findings constitute evidence justifying further studies 
of the frequency of MET germline mutations in high-
risk populations, the role of MET inhibitors in cancer 
prevention, and the use of MET-T1010I as biomarker 
for inclusion of patients in therapeutic studies of MET 
inhibitors. 
METHODS
Human tissues
Clinical information
Tumor and blood samples were obtained under a 
prospective collection protocol at MD Anderson Cancer 
Center (MDACC). After informed consent, patients 
with metastatic breast cancer underwent biopsy of their 
metastatic disease and blood collection. Patients and 
tumor characteristics were collected by chart review. The 
Institutional Review Board of MDACC approved the 
laboratory study. Patients with metastatic breast cancer 
were categorized according to MET germline mutations 
(mutant versus wild type). Patients’ characteristics 
including age, race, tumor size, lymph nodes, pathologic 
stage, histology, grade, lymphovascular invasion, and 
(neo)adjuvant chemotherapy were tabulated and compared 
between groups using Fisher’s exact test. Overall survival 
(OS) was measured from the date of diagnosis to the date 
of death or lost to follow-up. The Kaplan-Meier product 
limit method was used to estimate the survival outcomes 
of all patients by groups and was compared using the log-
rank statistic.
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Genomic DNA and library preparation
Genomic DNA was quantified by Qubit (Invitrogen) 
and quality was accessed using Genomic DNA Tape for 
the 2200 Tapestation (Agilent). DNA from each sample 
(200-500 ng of genomic DNA) was sheared by sonication 
with the following conditions: Peak Incident Power 175, 
Duty Cycle 20%, Intensity 5, Cycles per Burst 200, and 
120 seconds using Covaris E220 instrument (Covaris). To 
ensure the proper fragment size, samples were checked on 
TapeStation using the DNA High Sensitivity kit (Agilent). 
The sheared DNA proceeded to library prep using KAPA 
library prep kit (KAPA) following the “with beads” 
manufacturer protocol. Briefly, this protocol consists of 
3 enzymatic reactions for end repair, A-tailing and BioO 
adaptor ligation, followed by barcode (BioO) insertion 
by PCR using KAPA HiFi polymerase (6 cycles). PCR 
primers were removed by using 1.8x volume of Agencourt 
AMPure PCR Purification kit (Agencourt Bioscience 
Corporation). At the end of the library prep, samples 
were analyzed on TapeStation to verify correct fragment 
size and to ensure the absence of extra bands. Samples 
were quantified using KAPA qPCR quantification kit. 
Equimolar amounts of DNA were pooled for capture (8-
12 samples per pool). 
Targeted capture
202 genes including MET that are clinically relevant 
in cancer, based on mutational data in the Catalogue of 
Somatic Mutations in Cancer (COSMIC) and The Cancer 
Genome Atlas (TCGA) with a minimum of 3% frequency 
across disease sites or 5% disease specific were selected 
for capture. We designed biotin labeled probes with Roche 
Nimblegen for capturing target regions (all exons in those 
202 genes) and followed manufacture’s protocol for the 
capture step. Briefly, DNA was pooled (8-16 samples), 
dried out and after addition of the capture reagents and 
probes; samples were incubated at 47oC on thermocycler 
with heated lid (57oC) for 64−74 hours. The targeted 
regions were recovered using streptavidin beads and the 
streptavidin-biotin-probe-target complex was washed 
and another round of PCR amplification was performed 
according to manufacturer’s protocol. The quality of 
each captured sample was analyzed on TapeStation using 
the DNA High Sensitivity kit and the enrichment was 
accessed by qPCR using specific primers designed by 
Roche Nimblegen. The cutoff for the enrichment was 50-
fold minimum.
Sequencing
The captured libraries were sequenced on a HiSeq 
2000 (Illumina Inc., San Diego, CA, USA) on a version 3 
TruSeq paired end flowcell according to manufacturer’s 
instructions at a cluster density between 700 –1000 K 
clusters/mm2. Sequencing was performed on a HiSeq 
2000 for 2 × 100 paired end reads with a 7 nt read for 
indexes using Cycle Sequencing v3 reagents (Illumina). 
The resulting BCL files containing the sequence data were 
converted into “.fastq.gz” files and individual libraries 
within the samples were demultiplexed using CASAVA 
1.8.2 with no mismatches. All regions were covered by 
>20 reads.
Data Analysis
We aligned the T200 target-capture deep-sequencing 
data to human reference assembly GRCh37 using BWA 
[24] and removed duplicated reads using Picard [25]. We 
called single nucleotide variants (SNVs) and small indels 
using an in-house developed analysis pipeline [26], which 
classified variants into 3 categories: somatic, germline, and 
loss of heterozygosity based on variant allele frequencies 
in the tumor and the matched normal tissues. We called 
copy number alterations using a previously published 
algorithm [27], which reports gain or loss status of each 
exon. To understand the potential driver identity and 
functional consequence of detected variants, we compared 
them with dbSNP, COSMIC [28], and TCGA databases, 
and annotated them using VEP [29], ANNOVAR [30] and 
CanDrA [31].
Cell lines and animal models
Construction of recombinant lentiviruses 
expressing wild type and mutant MET
GeneART synthesized constructs expressing human 
wild type (WT) or mutant METs (MET-WT-Flag, MET 
-T1010I-Flag, and MET-Y1253D-Flag) were designed 
by us. pMA vector 2 was used as the backbone in these 
plasmids. The constructs were sequenced to ensure the 
validity of the sequence and the orientation. Then the 
human full-length cDNAs for wild type MET and the two 
mutants, with Kozak sequence before ATG and Flag-tag 
after MET, were sub-cloned into pLVX-tdTomato-N1 
vectors (Clontech, Mountain View, CA) with XhoI/Xmal 
enzymes. The constructs (pLVX-MET-WT-Flag-tdTomato, 
pLVX-MET-T1010T-Flag-tdTomato, pLVX-MET-Flag-
Y1253D and the empty vector pLVX-tdTomato-N1) were 
sequenced by GeneART to confirm the sequence. We 
confirmed that the orientation of the constructs was correct 
with restriction enzymes. 
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Generation of Lentiviruese expressing wild type 
and mutant METs
To generate the lentiviruses expressing wild type 
MET and its mutants, we used two expression systems. 
One of them was the ViraPower Lentiviral Expression 
System (Invitrogen). In addition, we used the Lenti-
XTM Lentiviral Expression System (Clontech). A total 
amount of 7 µg of pLVX-tdTomato-N1 vector, pLVX-
MET WT-Flag-tdTomato, pLVX-MET T1010T-Flag-
tdTomato, or pLVX-MET-Y1253D-Flag-tdTomato were 
co-transfected into the Lenti-X 293T cells, with 36 µg 
of the Lenti-X HTX packaging Mix, using 7.5 µl Xfect 
Polymer (Clontech, CA, USA). Lentiviruses containing 
supernatants were collected after 48 hours, followed by 
a brief centrifugation (500 g for 10 minutes) and passed 
through a 0.45 µm filter to remove cellular debris. Then 
they were used to infect the mammary epithelial cells. 
Selection began 48 hours after infection in growth medium 
with 1 µg/ml puromycin for two weeks. Both lentiviral 
expression systems allowed similar specific expression 
levels.
Cell culture
MCF-10A, non-transformed mammary epithelial 
cell lines obtained from our Characterized Cell Line 
Core, MDACC and grown at 37°C in humidified 5% CO2. 
MCF-10A cells were maintained in DMEM/F12 (Thermo 
Scientific, South Logan, Utah) supplemented with 5% 
horse serum (Invitrogen), 20 ng/ml EGF (Peprotech), 10 
µg/ml insulin (Sigma), 100 ng/ml cholera toxin (Sigma), 
0.5 µg/ml hydrocortisone (Sigma), 100 units/ml penicillin 
and 100 µg/ml streptomycin. Cells were frozen at early 
passages and used for less than 4 weeks in continuous 
culture.
Western Analyses
Cells were washed twice with cold phosphate-
buffered saline and lysed in ice-cold lysis buffer [1% 
Triton X-100, 50mM HEPES, pH 7.4, 150mM NaCl, 
1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM 
Na pyrophosphate, 1mM Na3VO4, 10% glycerol, 
protease inhibitor cocktail (Roche Applied Science), 
and phosphatase inhibitors, PhosSTOP (Roche Applied 
Science)]. Western blot was performed as described 
previously [32].
Morphogenesis Assay
Three-dimensional culture of cells was carried out 
on a Matrigel basement membrane [33]. Briefly, 4 x103 
cells were resuspended in a modified growth medium, 
containing 2% growth factor-reduced Matrigel (BD 
Biosciences), and subsequently seeded onto the Matrigel 
matrix in 8-well chamber slides (BD Bioscience). Medium 
was replaced every 3 days. Photographs of representative 
fields were taken as indicated. Acini were photographed 
and counted in 10 randomly chosen fields and expressed 
as means of triplicates, representative of three independent 
experiments.
In vitro Invasion Assay
Cell in-vitro invasion was analyzed with 24-
well Biocoat Matrigel invasion chambers with 8 µm 
polycarbonated filters (Becton Dickinson). Cells were 
starved for 20 hours in serum-free DMEM F12 lacking 
growth factors. A total of 1x105 cells in 0.6 ml DMEM 
F12 were inoculated into the upper chamber, and 0.75 
ml DMEM F12 containing fibronectin (5 µg/ml) with or 
without HGF (40 ng/ml) was added to the lower chamber. 
The cells were allowed to pass through the Matrigel at 
37°C, 5% CO2, for 22 hours. Non-invasive cells on the 
upper surface of the filter were removed by wiping with 
a cotton swab. The cells that penetrated through the pores 
of the Matrigel to the underside of the filter were stained 
with 0.25% crystal violet in 20% methanol for 30 minutes. 
Invasive cells were photographed and counted in 10 
random fields.
Clonogenic Assay
For clonogenic assays, 1,000 cells were seeded in a 
60 mm dish, in growth medium, for 11 days. For inhibitory 
assay, after attaching on the dish, cells were treated for 2 
days with drugs as designed. The cells were rinsed with 
PBS, followed by staining with 0.25% crystal violet / 20% 
ethanol. Quantitative analysis of the total number and size 
of clones was performed with AlphaVIEW SA software 
(Cell Biosciences).
Tumor Xenografts studies
All animal studies were carried out under ACUF-
approved protocols. hHGF Tg SCID females or hHGF 
negative littermates at 6-8 weeks of age were used. 
Exponentially growing MCF-10A derived cells, including 
MET-WT, MET-T1010I, MET-Y1253D, and control 
cells (vector), were harvested. After being washed, 1x107 
cells in growth factor reduced Matrigel and PBS (1:1), 
in total 200 µl, were injected into the mammary fat pads 
of mice. Each group consisted of 7-9 mice. Tumor sizes 
were determined by measuring the length (l) and the 
width (w) with calipers twice weekly. Tumor volume 
was calculated with the formula (V = lw2/2). Differences 
in tumor volume among groups at each time point were 
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analyzed using ANOVA. At the end of the experiment 
(28 days after tumor cell injection), mice were sacrificed. 
Tumors were harvested, followed by measurement of 
tumor size and weight. Tumors were cut and flash-frozen 
in liquid nitrogen for Western blot or fixed in 10% neutral-
buffered formalin for histopathological analysis. Fixed 
tissues were processed, embedded in paraffin, and cut in 
4 µm thick tissue sections that were stained with H&E 
for microscopic examination. Xenograft tumors and all 
the organs, of each mouse, were subjected to double-blind 
histopathological analysis by a veterinary pathologist.
Statistical Analyses
Statistical analyses were carried out using the 
ANOVA test (for multiple groups) and the Student t test 
(for two groups). Differences with P-values < 0.05 were 
considered statistically significant.
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